SIRPA and neoplasm: Moreover, by combining the recruitment and activation of FcRs via the antibody Fc domain and the blockade of CD47-SIRPα interaction by the endogenous low affinity CD47-antagonistic SIRPα domain, licMAB molecules significantly enhanced phagocytosis of tumor cells.